Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease

Citation
Rjf. Laheij et al., Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease, ALIM PHARM, 15(7), 2001, pp. 1055-1059
Citations number
16
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"da verificare
Journal title
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ISSN journal
0269-2813 → ACNP
Volume
15
Issue
7
Year of publication
2001
Pages
1055 - 1059
Database
ISI
SICI code
0269-2813(200107)15:7<1055:HPIAAR>2.0.ZU;2-Q
Abstract
Background: Aspirin use in the secondary prevention of ischaemic heart dise ase may provoke gastrointestinal discomfort. Objective: To register gastrointestinal symptoms and complications in patie nts with cardiovascular disease using aspirin and to relate these symptoms to infection with H. pylori. Methods: Blood samples were obtained from 398 consecutive patients in the C oronary-Care Unit, University Hospital Nijmegen and analysed for serum anti body levels to H. pylori infection. Questionnaires were sent 2 weeks after discharge to assess gastrointestinal symptoms. Results: Questionnaires were returned by 314 patients (79%). A total of 183 out of 314 patients (46%) reported gastrointestinal symptoms. Of 238 patie nts using 80-100 mg aspirin daily, 145 (61%) recorded gastrointestinal symp toms. Besides aspirin, the use of calcium antagonists was correlated with g astrointestinal symptoms, Of the 128 patients using calcium antagonists, 84 (66%) reported gastrointestinal symptoms. The prevalence of gastrointestin al symptoms in H. pylori-positive and -negative patients using aspirin was 48% and 52%, respectively. Conclusions: Two weeks after discharge almost 50% of the patients with card iovascular disease experienced gastrointestinal symptoms, especially patien ts using aspirin or calcium antagonists. Patients seropositive for H. pylor i and using aspirin or calcium antagonists did not have more gastrointestin al discomfort compared to non-infected patients.